Marimastat is a broad‐spectrum matrix inhibitor targeting matrix metalloproteinases (MMPs), including MMP‐2 and MMP‐9, demonstrating therapeutic potential for cholesteatoma‐related pathologies [49, 50]. This evidence concerns the gene MMP9 and cholesteatoma.